SAB Biotherapeutics (SABS) Expected to Announce Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $0.1250 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). On average, analysts expect SAB Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SAB Biotherapeutics Stock Up 1.6%

SAB Biotherapeutics stock opened at $3.85 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. SAB Biotherapeutics has a 1-year low of $1.85 and a 1-year high of $5.15. The company has a market cap of $294.37 million, a PE ratio of -1.82 and a beta of 0.53. The stock’s 50 day moving average price is $3.67 and its 200 day moving average price is $3.83.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Rodman & Renshaw reissued a “buy” rating and set a $13.00 price target on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Jefferies Financial Group started coverage on shares of SAB Biotherapeutics in a research note on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price objective on the stock. Citigroup began coverage on shares of SAB Biotherapeutics in a research note on Friday, May 22nd. They set a “buy” rating and a $11.00 price objective for the company. Leerink Partners raised their price target on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Finally, Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, SAB Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Institutional Investors Weigh In On SAB Biotherapeutics

Hedge funds have recently made changes to their positions in the business. Vivo Capital LLC acquired a new position in SAB Biotherapeutics in the third quarter valued at $22,954,000. RA Capital Management L.P. acquired a new stake in SAB Biotherapeutics in the 3rd quarter worth about $8,847,000. Woodline Partners LP purchased a new stake in SAB Biotherapeutics in the 3rd quarter valued at about $5,730,000. Perceptive Advisors LLC purchased a new stake in SAB Biotherapeutics in the 4th quarter valued at about $3,004,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of SAB Biotherapeutics during the 4th quarter valued at about $1,778,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.